Pegylated interferon-alfa 2b (Peg-IFN), INFα-2b covalently coupled with polyethylene glycol (Peg) that prolongs its circulation time in the blood, was approved by FDA in 2011 for the treatment of node-positive resected melanoma as an adjuvant therapy. Here, IFNA1 is linked to melanoma.